Analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) to post $303.53 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest sales estimate coming in at $323.00 million and the lowest estimate coming in at $286.31 million. Neurocrine Biosciences […]
First Hawaiian Bank acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 8,793 shares of the company’s stock, valued at approximately $749,000. Other large investors also recently modified their holdings […]
Perceptive Advisors LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 40.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 483,007 shares of the company’s stock after selling 328,825 shares during the period. Perceptive Advisors […]